The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Cytokinetics Inc shares valued at $904,200 were sold by Callos Andrew on Jan 05 ’26. At $60.28 per share, Callos Andrew sold 15,000 shares. The insider’s holdings dropped to 50,440 shares worth approximately $3.18 million following the completion of this transaction.
Also, Callos Andrew sold 1,798 shares, netting a total of over 112,585 in proceeds. Following the sale of shares at $62.62 each, the insider now holds 50,440 shares.
Before that, ANDREW CALLOS had added 59,570 shares to its account. In a trade valued at $3,785,078, the Officer bought Cytokinetics Inc shares for $63.54 each.
As published in a research note from Goldman on December 18, 2025, Cytokinetics Inc [CYTK] has been rated up from a Neutral to a Buy and the price target has been revised to $95. As of April 24, 2025, Barclays has initiated its “an Overweight” rating for CYTK. Earlier on February 07, 2025, Citigroup initiated its rating. Their recommendation was “a Buy” for CYTK stock.
Analyzing CYTK Stock Performance
On last trading session, Cytokinetics Inc [NASDAQ: CYTK] plunged -1.16% to $63.04. The stock’s lowest price that day was $62.71, but it reached a high of $64.765 in the same session. During the last five days, there has been a drop of approximately -0.46%. Over the course of the year, Cytokinetics Inc shares have jumped approximately 37.82%.
Is Cytokinetics Inc subject to short interest?
Stocks of Cytokinetics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.89 million shares to 13.84 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 12.95 million shares. A jump of 6.42% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 6.68 of the overall float, the days-to-cover ratio (short ratio) jumped to 6.68.
Which companies own the most shares of Cytokinetics Inc (CYTK)?
In terms of Cytokinetics Inc share price expectations, FactSet research, analysts set an average price target of 88.5 in the next 12 months, up nearly 38.76% from the previous closing price of $63.78. Analysts anticipate Cytokinetics Inc stock to reach 136 by 2026, with the lowest price target being 61. In spite of this, 12 analysts ranked Cytokinetics Inc stock as Buy at the end of 2026. On January 22, 2025, Stifel assigned a price target of “a Buy” to the stock and initiated coverage with a $80.
